- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02211950
Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers
7. August 2014 aktualisiert von: Boehringer Ingelheim
Evaluation of Relative Bioavailability of BI 44847 in Different Ethnic Groups (Subjects of White, Asian, and African Origin), and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers. An Open-label, Single-dose, Parallel Group, Phase 1 Study (Group 1 With Additional Crossover Aspects)
The objectives were to investigate the relative bioavailability of BI 44847 in different racial groups (white, Asian, and African subjects) and to investigate the effect of different types of diet and acarbose coadministration on the bioavailability of BI 44847 in white subjects.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
37
Phase
- Phase 1
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 40 Jahre (Erwachsene)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Männlich
Beschreibung
Inclusion Criteria:
- Healthy male subjects determined by results of screening
- Age 18 - 40 years
- Body Mass Index 18 - 25 kg/m2, at least 45 kg
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
Exclusion Criteria:
- Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator
- Relevant gastrointestinal tract surgery
- Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or relevant neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, pulse rate out of 45 to 90 beats per minute
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergies) that are deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation
- Participation in another trial with an investigational drug within 2 months after a multiple dose study or within 1 month after a single dose study
- Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
- Inability to refrain from smoking when confined to the study site on trial days
- Alcohol abuse (more than 60 g/day in males, more than 40 g/day in females)
- Drug abuse, in the investigator's judgment upon review of the patient's history and urine screening for abused substances
- Veins unsuited for iv puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture)
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within 48 hours prior to trial or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance according to the assessment of the investigator
- Inability to comply with dietary regimen of study centre
- Subjects not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment A
single dose BI 44847 administered to white subjects
|
|
Experimental: Treatment B
100 mg acarbose for 2 days, on the second day a single dose BI 44847 administered to white subjects
|
Andere Namen:
|
Experimental: Treatment C
single dose BI 44847 after a Japanese diet of 6 days administered to white subjects
|
|
Experimental: Treatment D
single dose BI 44847 administered to asian subjects
|
|
Experimental: Treatment E
single dose BI 44847 administered to african subjects
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Cmax (maximum concentration of the analyte in plasma)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
AUC0-∞ (area under the concentration time curve of the analyte in plasma in plasma over the time interval from 0 to infinity)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
AUC0-48 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 48 h)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
AUC0-12 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 12 h)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
tmax (time from dosing to maximum concentration of the analyte in plasma)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
λz (terminal rate constant in plasma after single dose
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
t1/2 (terminal half-life of the analyte in plasma after single dose)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
MRTpo (mean residence time of the analyte in the body after single dose)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
CL/F (apparent clearance of the analyte in the plasma after extravascular administration after single dose)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Vz/F (apparent volume of distribution during the terminal phase λz after single dose following extravascular administration)
Zeitfenster: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
AUCt1-t2 (area under the concentration time curve of analyte in plasma over the time interval t1 to t2)
Zeitfenster: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
Aet1-t2 (amount of drug that is eliminated in urine from the time point t1 to time point t2)
Zeitfenster: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
fet1-t2 (fraction of drug eliminated in urine from time point t1 to time point t2)
Zeitfenster: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
CLR,t1-t2 (renal clearance of the drug from the time point t1 until the time point t2)
Zeitfenster: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
Amount of glucose excreted in urine
Zeitfenster: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
Number of patients with adverse events
Zeitfenster: up to 48 hours after last administration of study drug
|
up to 48 hours after last administration of study drug
|
Number of patients with clinically relevant changes in laboratory tests
Zeitfenster: up to 48 hours after last administration of study drug
|
up to 48 hours after last administration of study drug
|
Number of patients with clinically relevant changes in Electrocardiogram (ECG)
Zeitfenster: up to 48 hours after last administration of study drug
|
up to 48 hours after last administration of study drug
|
Number of patients with clinically relevant changes in vital signs
Zeitfenster: up to 48 hours after last administration of study drug
|
up to 48 hours after last administration of study drug
|
Assessment of global tolerability by investigator on a 4-point scale
Zeitfenster: 48 hours after last administration of study drug
|
48 hours after last administration of study drug
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Nützliche Links
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Oktober 2008
Primärer Abschluss (Tatsächlich)
1. Dezember 2008
Studienanmeldedaten
Zuerst eingereicht
7. August 2014
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
7. August 2014
Zuerst gepostet (Schätzen)
8. August 2014
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
8. August 2014
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
7. August 2014
Zuletzt verifiziert
1. August 2014
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1224.22
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur BI 44847
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimAbgeschlossenDiabetes mellitus, Typ 2Deutschland, Niederlande
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimRekrutierungMelanom | Nicht-kleinzelliger Lungenkrebs (NSCLC) | Plattenepithelkarzinom von Kopf und Hals (HNSCC)Niederlande
-
Boehringer IngelheimZurückgezogenPlattenepithelkarzinom des AnalkanalsKorea, Republik von
-
Boehringer IngelheimBeendet
-
Boehringer IngelheimNoch keine Rekrutierung